Icahn School of Medicine at Mount Sinai

What Icahn School of Medicine at Mount Sinai does

Icahn School of Medicine at Mount Sinai (ISMMS) is a private nonprofit medical school founded in 1968 and located on Manhattan's Upper East Side, operating as the academic arm of the Mount Sinai Health System. It enrolls more than 1,200 students across MD, PhD, MD/PhD, and master's degree programs, trains 2,700+ residents and fellows in 150+ programs, and employs 6,900+ faculty across 38 academic departments and 47 research, educational, and clinical institutes spanning oncology, immunology, neuroscience, genetics, cardiology, public health, and digital health.

The institution's research infrastructure includes 350+ laboratories running an AI-augmented biomedical discovery stack that spans multi-agent LLM orchestration, computer vision for medical imaging, predictive analytics from genomic and EHR data, generative AI co-scientist platforms (e.g., Biomni-AD), and process-automation agents deployed in clinical workflows such as preprocedural patient communication. Notable platforms include a cSMRTS mRNA cell-targeting system, a microRNA-controlled mRNA vaccine platform, fully human monoclonal antibody technology, and a transformer-based cardiovascular risk model for sleep apnea patients. The Mount Sinai Tisch Cancer Center holds NCI Comprehensive Cancer Center designation, placing it in the top 1% of U.S. cancer centers.

Revenue is generated primarily through NIH and federal research grants ($501.7M in FY2025; $875M total research funding in CY2025), tuition and fees for degree programs, clinical care delivered through Mount Sinai Health System's seven hospital campuses, and industry partnerships and licensing (e.g., Nvidia AI-genomics collaboration, Bristol Myers Squibb cell therapy research, Immunai single-cell profiling initiative). The school ranks 11th among U.S. medical schools in NIH funding, with five departments in the top five nationally and 13 departments in the top 20 NIH-funded institutions.

Name

Icahn School of Medicine at Mount Sinai

Legal name

Icahn School of Medicine at Mount Sinai

Website

https://icahn.mssm.edu

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Icahn School of Medicine at Mount Sinai is a private nonprofit medical school and biomedical research institution serving 1,200+ students, 2,700+ residents/fellows, and 6,900+ faculty, with $875M in research funding and a top-tier NIH-funded research portfolio.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

General Medical and Surgical Hospitals (6221), Colleges, Universities, and Professional Schools (6113)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

Keywords

• Medical education
• Biomedical research
• Graduate medical training
• Clinical research services
• Translational medicine

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Grants and Funding: Primary research funding from NIH and other federal agencies. NIH funding awarded in fiscal year 2025 was $501.7 million. Total research funding in calendar year 2025 was $875 million. Additional funding from private foundations including Helmsley Charitable Trust, NIH NCI, and others.
2. Tuition and Fees: Revenue from medical school, graduate school, and continuing education programs for MD, PhD, MD-PhD, and master's degree programs.
3. Clinical Care Services: Mount Sinai Health System clinical operations including seven hospital campuses providing patient care services, generating revenue through healthcare delivery.
4. Industry Partnerships and Collaborations: Collaborative research with technology partners like Nvidia and pharmaceutical companies including Bristol Myers Squibb, generating revenue through research partnerships and licensing agreements.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Icahn School of Medicine at Mount Sinai is a private nonprofit academic medical institution that provides medical education (MD, PhD, MD-PhD, and master's degree programs), graduate medical training (residencies and fellowships across 150+ specialties), postdoctoral training, and biomedical research. The institution operates 350+ research laboratories and 47 research, educational, and clinical institutes spanning cancer, genomics, immunology, neurosciences, cardiovascular medicine, and precision medicine, while delivering patient care through the Mount Sinai Health System's seven hospital campuses.

Product overview

The Icahn School of Medicine at Mount Sinai is an academic medical institution offering medical education, graduate programs, residency/fellowship training, postdoctoral programs, nursing education, and clinical research services. It does not offer commercial software products or technology platforms for external use. Research activities span fundamental science, clinical trials, and translational medicine across 28 research institutes covering areas including cancer (Tisch Cancer Center), genomics, immunology, neurosciences, cardiovascular research, and digital health.

Differentiator

Problem solved

Functional benefit

Products and services

• MD Program
• Graduate School of Biomedical Sciences
• Residency and Fellowship Programs
• Postdoctoral Training Program
• Nursing School
• Public Health Programs
• Continuing Medical Education
• Clinical Trials Program

Quantifiable outcome

• NIH funding of $501.7 million in fiscal year 2025
• +7 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature8 records

Partnerships

17 partnerships are on record, tiered minor and core.

• IGC PharmaminorStrategic or Co-development Partner · 2 June 2026Clinical trial site partnership for Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. Trial approximately 80% complete with database lock and topline analysis progressing.
• University of Texas at AustincoreStrategic or Co-development Partner · 5 February 2026Part of $11.6 million DoD-funded pivotal SAINT neuromodulation clinical trial for postpartum depression across four institutions including Icahn School of Medicine at Mount Sinai.
• University of Massachusetts Chan Medical SchoolcoreStrategic or Co-development Partner · 5 February 2026Lead institution for $11.6 million DoD-funded pivotal SAINT neuromodulation clinical trial for postpartum depression.
• Medical University of South CarolinacoreStrategic or Co-development Partner · 5 February 2026Part of $11.6 million DoD-funded pivotal SAINT neuromodulation clinical trial for postpartum depression across four institutions.
• ImmunaicoreStrategic or Co-development Partner · 12 January 2026Grand Collaboration Initiative for Single-Cell Immune Profiling with four academic research projects. Selected researchers receive free single-cell RNA sequencing and multi-omic data to support studies across autoimmune kidney disease, T-cell redirection therapy in multiple myeloma, neoadjuvant immunotherapy in NSCLC, and immunotherapy resistance in gastric cancer.
• NvidiacoreTechnology or Integration · 19 November 2025Three-year collaboration with Sheba Medical Center and Icahn School of Medicine at Mount Sinai to apply AI-driven large language model technology to genomic research. Investment of tens of millions of dollars to decode the human genome and advance disease prevention, diagnosis, and treatment.
• Rensselaer Polytechnic InstitutecoreStrategic or Co-development PartnerLong-standing collaboration producing the Center for Engineering and Precision Medicine with joint offices and labs in New York City. Focuses on basic research, therapeutic innovations, educating biomedical leaders, and producing healthcare products.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerResearch collaboration discovering that mezigdomide can rejuvenate exhausted T cells, enhancing effectiveness of CAR-T and bispecific antibody therapies for multiple myeloma. Preclinical data demonstrated amplified tumor-clearing capacity of CAR-T cells and bispecific antibodies.
• University of California, San DiegocoreStrategic or Co-development PartnerCollaborative research with Model Medicines on MDL-001, an oral broad-spectrum antiviral candidate demonstrating preclinical efficacy against four viral families, seven distinct viruses, and 13 variants/strains.
• University of OxfordcoreStrategic or Co-development PartnerPaired studies in Blood journal revealing mezigdomide's ability to reverse T cell exhaustion in multiple myeloma patients.
• University of California-San FranciscocoreStrategic or Co-development PartnerCollaboration identifying combination strategy to overcome immunotherapy resistance in colorectal cancer, achieving up to 100% tumor clearance in mismatch repair-deficient models.
• Texas Children'scoreStrategic or Co-development PartnerMulticenter clinical trial led by Icahn School of Medicine at Mount Sinai evaluating Medication Level Variability Index (MLVI) for organ rejection prevention in adolescent liver transplant patients across 13 pediatric transplant centers.
• CantargiaminorStrategic or Co-development PartnerResearch collaboration with Dr. Merad's group on nadunolimab (anti-IL1RAP antibody) showing synergistic effects with anti-PD-1 inhibitors in metastatic colorectal cancer. Clinical trial ongoing at Mount Sinai Tisch Cancer Center.
• Model MedicinescoreStrategic or Co-development PartnerCollaboration on MDL-001 broad-spectrum antiviral and ViroMME program for infectious disease pipeline advancement.
• Albert Einstein College of MedicinecoreStrategic or Co-development PartnerNew York Regional Diabetes Research Center partnership receiving $10.8 million NIH grant involving multiple institutions including Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine.
• Rosalind Franklin UniversityminorStrategic or Co-development PartnerNIH-funded collaboration ($1.7M) researching social recognition mechanisms in schizophrenia and autism spectrum disorders.
• Texas Children's Cancer and Hematology CenterminorStrategic or Co-development PartnerCollaboration developing the first preclinical model for Langerhans cell histiocytosis (LCH), enabling high-throughput drug validation and targeted therapies.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/icahnmountsinai
• YouTubeyoutube.com/user/MountSinaiSchool
• Facebookfacebook.com/IcahnMountSinai
• LinkedInlinkedin.com/company/icahn-school-of-medicine-at-moun
• Instagraminstagram.com/icahnmountsinai

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Icahn School of Medicine at Mount Sinai